Pfizer close to deal for Protalix drug in Brazil
Pfizer acquired the marketing rights to Protalix's Gaucher's disease treatment Uplyso in December.
Temorao spoke of a giant $730 million deal. Protalix declined to respond to the news or discuss the amount mentioned, but a quick calculation shows that the amount refers to the potential multi-year value.
Brazil has about 600 Gaucher's disease patients. Treatment for each Gaucher's disease patient costs several hundreds of thousands of dollars.
Gaucher's treatment in Brazil is through the government's health basket, so it is likely that if a contract like this is signed, it will turn Uplyso into the primary Gaucher's disease drug in the country. The price is likely to be slightly lower, owing to the bargaining power of such a central customer.
Nonetheless, it is possible to estimate the potential at $100-200 million per year. Under its agreement with Pfizer, Protalix is entitled to 40% of the revenue from sales of Uplyso.
Published by Globes [online], Israel business news - www.globes-online.com - on October 3, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options